Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Adcendo raises $135m as ADC funding frenzy continues Adcendo raised $135 million in funding to advance its portfolio of first-in-class ADCs into clinical trials Company’s ADC candidate, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 28 Nov 2024: Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline Allink Biotherapeutics has successfully raised $42 million in a Series […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: The first-in-class FGFR3 ADC of Qide Pharma commences clinical trials The U.S. FDA has granted clinical trial approval for GQ1011 (AMB302), a first-in-class ADC targeting fibroblast growth […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Blenrep + BorDex combination accepted for review by US FDA The U.S. FDA has accepted GSK’s Biologics License Application (BLA) for the use of Blenrep (belantamab mafodotin) […]
Weekly Digest – November 2024 Weekly Digest – November 2024 27 Nov 2024: Sacituzumab Tirumotecan Earns Approval in China for Pretreated Advanced TNBC Sacituzumab tirumotecan has been approved by China’s National Medical Products Administration (NMPA) to treat adult patients with […]
Weekly Digest – November 2024 Weekly Digest – November 2024 28 Nov 2024: AstraZeneca’s Enhertu breast cancer drug added to China’s state insurance list AstraZeneca’s breast cancer drug, Enhertu, will be included in China’s state-run health insurance scheme starting January […]
